Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Counseling | 10 | 2024 | 246 | 2.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 7 | 2025 | 76 | 1.610 |
Why?
|
| Genetic Testing | 15 | 2024 | 1105 | 1.460 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2025 | 3509 | 1.330 |
Why?
|
| Neoplasms | 11 | 2024 | 3035 | 1.180 |
Why?
|
| Disclosure | 2 | 2018 | 155 | 0.970 |
Why?
|
| Germ-Line Mutation | 9 | 2025 | 370 | 0.830 |
Why?
|
| Genomics | 11 | 2024 | 1678 | 0.820 |
Why?
|
| Counselors | 3 | 2024 | 24 | 0.780 |
Why?
|
| Oncologists | 2 | 2023 | 31 | 0.780 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 65 | 0.740 |
Why?
|
| Exome | 4 | 2024 | 1088 | 0.620 |
Why?
|
| Parents | 4 | 2024 | 1072 | 0.590 |
Why?
|
| Whole Genome Sequencing | 2 | 2018 | 325 | 0.540 |
Why?
|
| Interviews as Topic | 2 | 2018 | 428 | 0.530 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2017 | 28 | 0.530 |
Why?
|
| Haploinsufficiency | 2 | 2017 | 274 | 0.470 |
Why?
|
| Communication | 2 | 2018 | 542 | 0.460 |
Why?
|
| Research Subjects | 1 | 2015 | 55 | 0.440 |
Why?
|
| Genetic Research | 1 | 2015 | 56 | 0.440 |
Why?
|
| Death | 1 | 2015 | 80 | 0.430 |
Why?
|
| Child | 26 | 2025 | 25917 | 0.430 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2022 | 52 | 0.430 |
Why?
|
| Health Personnel | 2 | 2018 | 542 | 0.420 |
Why?
|
| Decision Making | 6 | 2024 | 701 | 0.410 |
Why?
|
| Ribonuclease III | 2 | 2025 | 103 | 0.400 |
Why?
|
| Professional-Family Relations | 3 | 2018 | 96 | 0.390 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 150 | 0.380 |
Why?
|
| Genome, Human | 5 | 2022 | 1350 | 0.380 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2025 | 20 | 0.370 |
Why?
|
| Intestinal Polyposis | 2 | 2022 | 18 | 0.360 |
Why?
|
| Transcription Factors | 5 | 2025 | 2735 | 0.340 |
Why?
|
| Humans | 44 | 2025 | 134194 | 0.320 |
Why?
|
| Informed Consent | 3 | 2019 | 345 | 0.320 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 1406 | 0.290 |
Why?
|
| Skin Neoplasms | 2 | 2025 | 907 | 0.270 |
Why?
|
| Medical Oncology | 2 | 2018 | 247 | 0.250 |
Why?
|
| Adult | 11 | 2024 | 31947 | 0.250 |
Why?
|
| Phenotype | 4 | 2019 | 4610 | 0.250 |
Why?
|
| Neuroblastoma | 2 | 2024 | 551 | 0.250 |
Why?
|
| Adolescent | 12 | 2025 | 20645 | 0.240 |
Why?
|
| Neurofibromin 2 | 1 | 2025 | 11 | 0.240 |
Why?
|
| Neurofibromatoses | 1 | 2025 | 10 | 0.240 |
Why?
|
| Neurofibromatosis 2 | 1 | 2025 | 10 | 0.240 |
Why?
|
| Leiomyomatosis | 1 | 2025 | 8 | 0.230 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 54 | 0.230 |
Why?
|
| SMARCB1 Protein | 1 | 2025 | 48 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 1344 | 0.230 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2025 | 23 | 0.230 |
Why?
|
| Costello Syndrome | 1 | 2024 | 17 | 0.230 |
Why?
|
| Neurilemmoma | 1 | 2025 | 48 | 0.230 |
Why?
|
| Noonan Syndrome | 1 | 2024 | 31 | 0.220 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 652 | 0.220 |
Why?
|
| Neurofibromatosis 1 | 1 | 2024 | 65 | 0.210 |
Why?
|
| Family | 2 | 2024 | 597 | 0.210 |
Why?
|
| Tuberous Sclerosis | 1 | 2025 | 124 | 0.210 |
Why?
|
| Information Seeking Behavior | 1 | 2023 | 16 | 0.210 |
Why?
|
| Health Literacy | 1 | 2024 | 79 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2025 | 262 | 0.200 |
Why?
|
| Meningioma | 1 | 2025 | 141 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 236 | 0.200 |
Why?
|
| Early Detection of Cancer | 2 | 2025 | 417 | 0.200 |
Why?
|
| Rare Diseases | 1 | 2025 | 209 | 0.200 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 40 | 0.190 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 54 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2025 | 217 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2025 | 216 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 18 | 0.190 |
Why?
|
| MyoD Protein | 1 | 2021 | 26 | 0.180 |
Why?
|
| Multilingualism | 2 | 2018 | 43 | 0.180 |
Why?
|
| Female | 16 | 2024 | 72035 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 294 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2024 | 128 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 628 | 0.170 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2020 | 31 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 87 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2021 | 361 | 0.170 |
Why?
|
| Trans-Activators | 1 | 2025 | 838 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 490 | 0.170 |
Why?
|
| Smad4 Protein | 1 | 2020 | 58 | 0.170 |
Why?
|
| Texas | 3 | 2024 | 3719 | 0.160 |
Why?
|
| Child, Preschool | 8 | 2024 | 14897 | 0.160 |
Why?
|
| Colectomy | 1 | 2020 | 84 | 0.160 |
Why?
|
| Male | 13 | 2025 | 66195 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2020 | 78 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 21 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 128 | 0.160 |
Why?
|
| Counseling | 1 | 2020 | 241 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 211 | 0.140 |
Why?
|
| Empathy | 1 | 2018 | 63 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 658 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 1013 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 75 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 448 | 0.140 |
Why?
|
| Cultural Competency | 1 | 2018 | 52 | 0.140 |
Why?
|
| Young Adult | 6 | 2024 | 9961 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2022 | 795 | 0.140 |
Why?
|
| Patients | 1 | 2018 | 127 | 0.140 |
Why?
|
| Telemedicine | 1 | 2024 | 507 | 0.140 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2017 | 13 | 0.140 |
Why?
|
| Pinealoma | 1 | 2017 | 23 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 469 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2017 | 57 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2017 | 45 | 0.130 |
Why?
|
| Language | 1 | 2018 | 222 | 0.130 |
Why?
|
| Germ Cells | 3 | 2024 | 204 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2017 | 105 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 2178 | 0.130 |
Why?
|
| Retinoblastoma | 1 | 2017 | 117 | 0.120 |
Why?
|
| Language Development Disorders | 1 | 2017 | 179 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 235 | 0.120 |
Why?
|
| Middle Aged | 5 | 2024 | 29413 | 0.120 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 253 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 571 | 0.110 |
Why?
|
| Professional Role | 1 | 2015 | 74 | 0.110 |
Why?
|
| Microcephaly | 1 | 2017 | 354 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 393 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 479 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 574 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 1051 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 65 | 0.100 |
Why?
|
| Heterozygote | 1 | 2014 | 732 | 0.090 |
Why?
|
| Polyps | 1 | 2012 | 44 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 641 | 0.090 |
Why?
|
| Infant | 4 | 2024 | 13262 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 983 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1167 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 572 | 0.090 |
Why?
|
| Stomach | 1 | 2012 | 272 | 0.080 |
Why?
|
| Mutation | 5 | 2025 | 6350 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 666 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1835 | 0.080 |
Why?
|
| Translating | 2 | 2018 | 31 | 0.070 |
Why?
|
| Aged | 2 | 2024 | 21805 | 0.070 |
Why?
|
| Homeodomain Proteins | 2 | 2024 | 589 | 0.070 |
Why?
|
| ras Proteins | 1 | 2024 | 146 | 0.050 |
Why?
|
| Siblings | 1 | 2024 | 202 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2025 | 112 | 0.050 |
Why?
|
| Population Groups | 1 | 2023 | 31 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 1187 | 0.050 |
Why?
|
| Uncertainty | 1 | 2023 | 104 | 0.050 |
Why?
|
| Quinolines | 1 | 2021 | 114 | 0.040 |
Why?
|
| Accreditation | 1 | 2020 | 94 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 118 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 239 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 220 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1125 | 0.040 |
Why?
|
| Linguistics | 1 | 2018 | 20 | 0.040 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2018 | 19 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 42 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2020 | 249 | 0.040 |
Why?
|
| Base Sequence | 1 | 2022 | 3180 | 0.040 |
Why?
|
| Pediatrics | 2 | 2017 | 1221 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 906 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 382 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 843 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 262 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 124 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1880 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 148 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2019 | 401 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 563 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 461 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 213 | 0.030 |
Why?
|
| United States | 2 | 2022 | 11798 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 421 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 298 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 376 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4008 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 237 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2997 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 965 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 681 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3180 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1854 | 0.020 |
Why?
|
| Health Behavior | 1 | 2014 | 405 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5465 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 648 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2562 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 36521 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5219 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3753 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 2051 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17579 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 19045 | 0.010 |
Why?
|